DesRosier Thomas sold 103 shares of Seres Therapeutics, Inc. at $1.38 for −$142 on Nov 16, 2026

Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
See Remarks
See Remarks
Filed Nov 17, 2026

Facts from the filing

Form 4 · Non-derivative, table I
Disclosed value
−$142.14Shares × reported price
Shares traded
103Common Stock
Price per share
$1.38Reported price. Read footnotes for ranges.
% of reported position traded
1.23%This security and ownership context
Holdings after
8,258Direct
Trade date
Nov 16, 2026Sell
Filed
Nov 17, 2026, 4:15 PM ET1-day reporting delay
Accession
0001193125-26-465538Code S · Transaction 403247
How reported position traded is calculated

Shares sold ÷ (holdings after + shares sold). Estimated position before: 8,361 shares.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Trade dateActivitySharesPriceValueDetails
Nov 15, 2026Option exercise133$0.00$0Trade 403248
Nov 15, 2026Option exercise111$0.00$0Trade 403249
Nov 15, 2026Option exercise244——Trade 403246
4 transaction rows in this filing. Joint filers share the same rows.

MCRB price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
MCRB · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.

Return windows are pending. The first 7-day window is eligible on Nov 24, 2026. Values appear when the daily price refresh supplies a valid close for that window. Weekends, market holidays and missing prices can delay updates.

Pre-filing1mo ago +37%1w ago 0%1d ago 0%
Returns since7d30d90d180d1y

Footnotes in full

F1: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F2: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on March 2, 2023, solely with the intent to cover taxes in connection with the vesting of the restricted stock units. F3: The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date. F4: The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2025. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date.